TY - JOUR
T1 - A Novel Mini-invasive Approach to the Treatment of Neuropathic Pain: The PENS Study
AU - Rossi, Marco
AU - De Carolis, Giuliano
AU - Liberatoscioli, Goffredo
AU - Iemma, Domenico
AU - Nosella, Paola
AU - Nardi, Luigi F.
PY - 2016
Y1 - 2016
N2 - Background: Peripheral neuromodulation is often used as chronic neuropathic pain treatment. Percutaneous electrical nerve stimulation (PENS) is generally utilized with several probes at the same time and repeated treatments.Objectives: Evaluate the short-and long-term efficacy of a single probe and single shot PENS approach. Study Design: Multicenter, prospective, observational study.Setting: Four Italian pain therapy centers.Methods: Inclusion criteria were age >= 18 and <= 80 years, presence of severe peripheral neuropathic pain lasting more than 3 months, localized and refractory to pharmacological therapies. Patients with infection, coagulopathies, psychiatric disorders, pacemakers, or implantable cardiac defibrillators were excluded.Patients: Seventy-six patients (47 women, 29 men), mean age 62 +/- 14 years, affected by neuralgia (21 herpes zoster infection, 31 causalgia, 24 postoperative pain) were enrolled in the study. Intervention: After localization of trigger point and/or allodynic/hyperalgesic area, PENS therapy was achieved with a single 21 gauge conductive probe tunneled percutaneously and a neurostimulator device.Measurement: Numerical Rating Scale (NRS) and Neuropathic Pain Scale (NPS) were assessed at baseline, 60 minutes after PENS, at one week, after one, 3, and 6 months; perceived health outcome was measured with Euroqol-5 dimension (EQ-5D) questionnaire at baseline and at 6 months. Adverse events and patient satisfaction were reported.Results: NRS and NPS decreased significantly after 60 minutes and the reduction remained constant over time at follow-up. EQ-5D increased significantly with respect to the baseline. Two nonclinically significant adverse events (one contralateral dysestesia and one self-resolving hematoma) were observed.Limitations: Small sample size and non-randomized observational study; high prevalence of post-herpetic and occipital neuralgias.Conclusion: PENS therapy produced significant and long-lasting pain relief in chronic peripheral neuropathic pains of different etiology. The present study confirms the feasibility, safety, and repeatability of this minimally invasive technique.
AB - Background: Peripheral neuromodulation is often used as chronic neuropathic pain treatment. Percutaneous electrical nerve stimulation (PENS) is generally utilized with several probes at the same time and repeated treatments.Objectives: Evaluate the short-and long-term efficacy of a single probe and single shot PENS approach. Study Design: Multicenter, prospective, observational study.Setting: Four Italian pain therapy centers.Methods: Inclusion criteria were age >= 18 and <= 80 years, presence of severe peripheral neuropathic pain lasting more than 3 months, localized and refractory to pharmacological therapies. Patients with infection, coagulopathies, psychiatric disorders, pacemakers, or implantable cardiac defibrillators were excluded.Patients: Seventy-six patients (47 women, 29 men), mean age 62 +/- 14 years, affected by neuralgia (21 herpes zoster infection, 31 causalgia, 24 postoperative pain) were enrolled in the study. Intervention: After localization of trigger point and/or allodynic/hyperalgesic area, PENS therapy was achieved with a single 21 gauge conductive probe tunneled percutaneously and a neurostimulator device.Measurement: Numerical Rating Scale (NRS) and Neuropathic Pain Scale (NPS) were assessed at baseline, 60 minutes after PENS, at one week, after one, 3, and 6 months; perceived health outcome was measured with Euroqol-5 dimension (EQ-5D) questionnaire at baseline and at 6 months. Adverse events and patient satisfaction were reported.Results: NRS and NPS decreased significantly after 60 minutes and the reduction remained constant over time at follow-up. EQ-5D increased significantly with respect to the baseline. Two nonclinically significant adverse events (one contralateral dysestesia and one self-resolving hematoma) were observed.Limitations: Small sample size and non-randomized observational study; high prevalence of post-herpetic and occipital neuralgias.Conclusion: PENS therapy produced significant and long-lasting pain relief in chronic peripheral neuropathic pains of different etiology. The present study confirms the feasibility, safety, and repeatability of this minimally invasive technique.
KW - Neuropathic pain
KW - neuromodulator
KW - percutaneous stimulation
KW - peripheral nerve
KW - Neuropathic pain
KW - neuromodulator
KW - percutaneous stimulation
KW - peripheral nerve
UR - http://hdl.handle.net/10807/172428
M3 - Article
SN - 1533-3159
VL - 19
SP - E121-E128
JO - Pain Physician
JF - Pain Physician
ER -